[ePublic Notice Highlights] SK바사 Submits COVID Vaccine for WHO Emergency Use Listing, etc. (Morning Summary)

[Asia Economy Reporter Kwon Jaehee] SK Bioscience announced on the 8th that it submitted the emergency use listing (EUL) application documents for its COVID-19 vaccine SKYCovione (GBP510) to the World Health Organization (WHO) the previous day.

The company stated, "We plan to pursue WHO EUL registration and global supply going forward."

Below are the major disclosures released this morning.

▲ HanmiGlobal = HanmiGlobal announced on the 8th that it signed a supervision and project management service contract for Samsung Electronics' P4L production facility in Pyeongtaek. The contract amount is approximately 33.8 billion KRW, which corresponds to 12.5% of the 2021 sales revenue. The contract period is from February 18, 2022, to January 31, 2024.

▲ Daehwa EL = Outside director Yoon Kwang-ho voluntarily resigned during his term on the 8th, reducing the number of outside directors from three to two, the company announced on the 8th.

▲ E-Mart = E-Mart disclosed on the 8th that its sales in August reached 1.4527 trillion KRW, an 8.1% increase compared to the previous month. Sales also rose 9.9% compared to the same month last year.

▲ EightOne = The company announced on the 8th that it signed a service contract with Jecheon City, Chungcheongbuk-do, for the production of immersive content and the establishment of an experience zone at the Uirimji History Museum. The contract amount is 370.9 million KRW, which corresponds to 10.58% of the 2021 sales revenue. The contract period is from September 13 to March 11, 2023.

▲ IA = To stabilize its stock price and enhance shareholder value, the company announced on the 8th that it will acquire 1 million treasury shares through on-market purchases for 713 million KRW. The acquisition period is from September 13 to December 12.

▲ Genofocus = Regarding media reports stating "Top enzyme company Genofocus likely to be acquired by Lotte," the company disclosed that "various strategic options are being reviewed to strengthen business competitiveness, but no decisions have been made."